XOMA Corp Pref Share 8.625 Perp 12/15/21 | 8-K: FY2025 Q2 Revenue: USD 13.13 M

Revenue: As of FY2025 Q2, the actual value is USD 13.13 M.

EPS: As of FY2025 Q2, the actual value is USD 0.44.

Segment Revenue

• XOMA Royalty received $29.6 million in cash from partners in the first half of 2025, with $16.0 million from royalty payments related to commercial sales and $13.6 million from milestone payments and fees.

Operational Metrics

• Net income for the three and six months ended June 30, 2025, was $9.2 million and $11.6 million, respectively, compared to $16.0 million and $7.4 million for the corresponding periods of 2024.
• General and Administrative (G&A) expenses for the three and six months ended June 30, 2025, were $7.8 million and $15.9 million, respectively, compared to $11.0 million and $19.5 million for the corresponding periods of 2024.

Cash Flow

• Net cash provided by operating activities was $8.7 million for the six months ended June 30, 2025.
• Net cash used in investing activities was - $26.7 million for the six months ended June 30, 2025.
• Net cash used in financing activities was - $9.9 million for the six months ended June 30, 2025.

Unique Metrics

• XOMA Royalty deployed $20 million to acquire additional economics in mezagitamab and repurchased approximately 81,700 shares of its common stock for a cost of $1.8 million during the second quarter of 2025.

Outlook / Guidance

• XOMA Royalty anticipates becoming cash flow positive on a consistent basis exclusively from cash payments received from royalties as new commercial opportunities emerge within its portfolio.